TITLE

FDA Panel Rejects New Obesity Drug

PUB. DATE
August 2010
SOURCE
Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the Food and Drug Administration (FDA) panel has rejected the approval of the anti-obesity drug Qnexa of Vivus Inc. in the U.S.
ACCESSION #
52817415

 

Related Articles

  • Vivus' Qnexa is Likely to Face Delay.  // Bioworld Week;7/26/2010, Vol. 18 Issue 30, p2 

    The article reports on the impact of the decision of the Food and Drug Administration (FDA) to withhold the approval of Vivus Inc.'s obesity drug Qnexa on the business revenue of California-based Vivus Inc.

  • Vivus Gains ED Approval; Obesity Still Center Stage. Morrison, Trista // BioWorld Today;4/30/2012, Vol. 23 Issue 83, p1 

    The article reports that Vivus Inc. has gained a U.S. Food and Drug Administration's (FDA) approval for erectile dysfunction (ED) drug Stendra in April 27, 2012. Stendra becomes the latest competitor to Pfizer Inc.' Viagra and Eli Lilly and Co.'s Cialis. Despite the approval, Stendra's stocks...

  • Qnexa's Fate to Serve as a Guide for Other Obesity Drugs. Serebrov, Mari // BioWorld Today;7/12/2012, Vol. 23 Issue 134, p1 

    The article focuses on Vivus Inc.'s drug application with the U.S. Food and Drug Administration (FDA) for its weight-loss drug Qnexa. The drug combines phentermine, an appetite suppressant, with an anticonvulsant topiramate. If approved, it will open up a new lane for weight-loss drugs...

  • Vivus Plans New Study, 4Q Qnexa NDA Resubmission. Wall, Tom // BioWorld Today;5/4/2011, Vol. 22 Issue 86, p1 

    The article reports that Vivus Inc. of Mountain View, California expects to resubmit a drug application for obesity drug Qnexa in the fourth quarter of 2011. The drug was rejected by the U.S. Food and Drug Administration (FDA) in October 2010 because the agency wanted additional data about the...

  • FDA's Request Shakes Up Vivus Stock, Qnexa Timeline. Wall, Tom // BioWorld Today;1/24/2011, Vol. 22 Issue 15, p1 

    The article reports on the request made by the U.S. Food and Drug Administration (FDA) for more data about the incidence of birth defects in children born to women using topiramate, a component in Qnexa developed by Vivus Inc. The news has affected the stock and plans of the company for FDA...

  • Vivus Reaps Evamist Approval, $140M.  // Bioworld Week;8/6/2007, Vol. 15 Issue 32, p2 

    The article reports on the success of Mountain View, California-based pharmaceutical company Vivus Inc. to win the U.S. Food and Drug Administration (FDA) approval of its Evamist product, which lead the company to acquire $140 million partnership payment. The FDA approved the product, a...

  • Obesity Drug Competition Set to Begin, Finally. Orelli, Brian // BioWorld Insight;6/10/2013, Vol. 21 Issue 24, p2 

    The article provides information on the launch of various drugs for the treatment of patients suffering from obesity and their effect on the market. It informs that Arena Pharmaceuticals Inc. based in California has launched obesity drug Belviq, approved by the U.S. Food and Drug Administration...

  • Stock Frenzy After Surprisingly Positive EMDAC Vote on Qnexa. Catherine Shaffer // BioWorld Today;2/24/2012, Vol. 23 Issue 37, p1 

    The article reports on an increase in the share price of Vivus Inc. on February 23, 2012 in response to a positive by the U.S. Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for its weight loss candidate Qnexa. Its share price rose by 8.18 U.S....

  • Vivus Hopes Second Time's a Charm for Qnexa in Obesity. Serebrov, Mari // BioWorld Today;2/21/2012, Vol. 23 Issue 34, p2 

    The article deals with the second application of Vivus Inc. for its obesity drug Qnexa to the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). Noted are the efforts made by Vivus to prepare for its second application, which include gathering more information about cardiovascular...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics